Poseida Therapeutics, Inc. Increase (Decrease) in Accounts Receivable
Poseida Therapeutics, Inc. reported Increase (Decrease) in Accounts Receivable of $5.74 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2024-11-07
- Poseida Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-09-30 was $2.32M.
- Poseida Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-06-30 was $400.00K, a 88.47% decline year-over-year.
- Poseida Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2024-03-31 was $3.02M.
- Poseida Therapeutics, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-12-31 was $338.00K.
- Poseida Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2023 was -$77.00K, a 100.85% decline from fiscal 2022.
- Poseida Therapeutics, Inc. increase (decrease) in accounts receivable for fiscal 2022 was $9.09M.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2024-09-30 | $2.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.72M derived: sum of 2 quarters · filed 2024-11-07 | $5.74M 10-Q · filed 2024-11-07 | $6.08M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $400.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $3.42M 10-Q · filed 2024-08-05 | $3.75M derived: sum of 3 quarters · filed 2024-08-05 | $521.00K derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $3.02M 10-Q · filed 2024-05-14 | $3.35M derived: sum of 2 quarters · filed 2024-05-14 | $121.00K derived: sum of 3 quarters · filed 2024-11-07 | $3.59M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | -$2.90M derived: sum of 2 quarters · filed 2024-11-07 | $573.00K derived: sum of 3 quarters · filed 2024-11-07 | -$77.00K 10-K · filed 2024-03-07 |
| 2023-09-30 | -$3.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $235.00K derived: sum of 2 quarters · filed 2024-11-07 | -$415.00K 10-Q · filed 2024-11-07 | -$29.79M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $3.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $2.82M 10-Q · filed 2024-08-05 | -$26.56M derived: sum of 3 quarters · filed 2024-08-05 | $11.67M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | -$650.00K 10-Q · filed 2024-05-14 | -$30.03M derived: sum of 2 quarters · filed 2024-05-14 | $8.21M derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$29.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-07 | $8.86M derived: sum of 2 quarters · filed 2024-03-07 | $9.09M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $38.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $38.47M 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $232.00K 10-Q · filed 2023-08-08 |